Traditionally, breast cancer prognosis and classification have relied on analysis of tumor morphology and expression of three markers, i.e., estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor2 (HER2). This evidence concerns the gene ESR1 and neoplasm.